Trial Profile
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Capecitabine; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 08 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 08 Jan 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Dec 2025.
- 08 Aug 2022 Results published in the Lancet Oncology